Showing results (731-740 of 792) with videos related to
Sort By:
Pageof 80
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Blood|June 26, 2014
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisDamiano Rondelli, Judith D Goldberg, Luis Isola, et al.Leukemia Research|March 9, 2018
AML refractory to primary induction with Ida-FLAG has a poor clinical outcomeSimon Kavanagh, Emily Heath, Rose Hurren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2015
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Uday Popat, Laura C Michaelis, et al.British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Journal of Hematopathology|May 16, 2026
VEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohortDheeraj Chinnam, Aadya Kerkar, Rohit Gulati, et al.The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Haematologica|July 10, 2025
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemiaTracy Murphy, Boyang Zhang, Tong Zhang, et al.Cancer|January 25, 2017
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysisFotios V Michelis, Vikas Gupta, Mei-Jie Zhang, et al.Pageof 80